SANDOZ DIMETHYL FUMARATE CAPSULE (DELAYED RELEASE)

Pajjiż: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

DIMETHYL FUMARATE

Disponibbli minn:

SANDOZ CANADA INCORPORATED

Kodiċi ATC:

L04AX07

INN (Isem Internazzjonali):

DIMETHYL FUMARATE

Dożaġġ:

240MG

Għamla farmaċewtika:

CAPSULE (DELAYED RELEASE)

Kompożizzjoni:

DIMETHYL FUMARATE 240MG

Rotta amministrattiva:

ORAL

Unitajiet fil-pakkett:

100

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0154210002; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2021-10-04

Karatteristiċi tal-prodott

_Sandoz Dimethyl Fumarate _
_Page 1 of 46 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR SANDOZ DIMETHYL FUMARATE
dimethyl fumarate delayed-release capsules
delayed-release capsules, 120 mg and 240 mg, oral
Antineoplastic and Immunomodulating Agents
Sandoz Canada Inc.
110 Rue de Lauzon
Boucherville, (Québec), Canada
J4B 1E6
Date of Initial Authorization:
October 4, 2021
Date of Revision:
May 19, 2022
Submission Control Number: 259700
_Sandoz Dimethyl Fumarate _
_Page 2 of 46 _
RECENT MAJOR LABEL CHANGES
1 INDICATIONS, 1.1 Pediatrics
05/2022
2 CONTRAINDICATIONS
05/2022
4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and Dosage
Adjustment
05/2022
7 WARNINGS AND PRECAUTIONS, Hematologic
05/2022
7 WARNINGS AND PRECAUTIONS, Immune
05/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
..................................................................................................
2
TABLE OF
CONTENTS...................................................................................................................
2
PART I: HEALTH PROFESSIONAL
INFORMATION..............................................................................
4
1
INDICATIONS
......................................................................................................................
4
1.1
P
EDIATRICS
..........................................................................................................................
4
1.2
G
ERIATRICS
..........................................................................................................................
4
2
CONTRAINDICATIONS..........................................................................................................
4
4
DOSAGE AND ADMINISTRATION
...........................................................................................
5
4.1
D
OSING
C
ONSIDERATI ONS
..............................................................................................